Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial
| Autor: | Supanat Burinkul, Punkavee Tuntiviriyapun, Ammarin Suwan, Sorawit Wainipitapong, Krasean Panyakhamlerd |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Urology Endocrinology Diabetes and Metabolism medicine.medical_treatment Population Spironolactone Transgender Persons law.invention chemistry.chemical_compound Endocrinology Randomized controlled trial law Internal medicine medicine Humans Testosterone Cyproterone Cyproterone Acetate education education.field_of_study business.industry Estradiol valerate Cyproterone acetate Androgen Antagonists Psychiatry and Mental health Reproductive Medicine chemistry Estrogen Female Hormone therapy business Transsexualism medicine.drug |
| Zdroj: | The Journal of Sexual Medicine. 18:1299-1307 |
| ISSN: | 1743-6109 1743-6095 |
| Popis: | Background Spironolactone and cyproterone acetate are commonly used in feminizing hormone therapy to achieve the goal of female range testosterone level; however, the data on the efficacy comparing between these two anti-androgens are scarce. Aim To compare the anti-androgenic effects between spironolactone and cyproterone acetate as the component of feminizing hormone therapy among transgender women population. Methods The study was single-blinded randomized controlled trial involved 52 transgender women from two transgender health clinics. Each participant received oral estradiol valerate 4 mg/day combined with anti-androgen, spironolactone 100 mg/day or cyproterone acetate 25 mg/day, depending on which group they were randomized to. Clinical and biochemical variables were obtained at baseline and at 12 weeks of feminizing hormone therapy. Main Outcome Measures The change of testosterone level from baseline. Other changes including free testosterone, estradiol, prolactin and lipid profile after the therapy. RESULTS After a 12 weeks of feminizing hormone therapy, the change of testosterone level in the cyproterone acetate group [558.0 ng/dL (IQR 352.0 to 783.3)] was significantly higher than the spironolactone group [226.2 ng/dL (IQR,-4.3 to 480.1)](p value Clinical Implications The data on the differences between the two anti-androgen could be benefit for the transgender health-care providers in medication selection and adverse-effects counseling. Strengths & Limitations The study design was randomized controlled trial and controlled the estrogen component by prescribed the same type and dose for each participant. However, the study was suffered from the confound feminizing effects from previous hormone therapy and the high drop-out rate. CONCLUSION For feminizing hormone therapy, cyproterone acetate had a higher testosterone suppression efficacy than spironolactone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|